ViraTherapeutics is a biotechnology company developing a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. Since 2018 ViraTherapeutics is part of the Boehringer Ingelheim group of companies and is embedded in the corporate Discovery Research organization.